Natalizumab

Table   Graphic     exposition period:

Congenital malformations
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
All congenital malformations (majors, minors, majors and minors, or unspecified)5.51 [1.10, 27.66]-1 study954not evaluable ROB10.50 [1.43; .]
2 non statistically significant endpoints reported in only one study

Growth parameters and prematurity
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Preterm (< 37 weeks)0.84 [0.46, 1.52]31%2 studies235111not evaluable ROB-
Low birth weight (< 2500g)--0 study-

Maternal consequences
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Caesarean--0 study-
Maternal consequences (as a whole)3.50 [1.02, 12.05]-1 study1354not evaluable ROB6.46 [1.15; .]

Intrauterine deaths
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Elective/induced termination of pregnancy2.26 [0.33, 15.52]82%2 studies48147not evaluable ROB-
4 non statistically significant endpoints reported in only one study

Neuro-developmental disorders
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
1 non statistically significant endpoints reported in only one study